Aim Sofosbuvir is a key agent for HCV treatment. It is not recommended for patients with
chronic kidney disease (CKD) and estimated glomerular filtration rate (eGFR)< 30 mL/min …

Abstract Background and Aims There is sparse data on the use of Sofosbuvir based directly
acting antiviral (DAA) drug regimens in chronic hepatitis C (CHC) patients with chronic …

Background Sofosbuvir is not recommended in persons with estimated glomerular filtration
rate (eGFR)< 30 mL/min. We report the results of treatment with an off-label 8-week regimen …

Abstract Background and Aim Many of the treatment regimens available for hepatitis C
include sofosbuvir. Unfortunately, sofosbuvir has not been recommended for use in patients …

Abstract Background & Aims There is scant data on use of sofosbuvir containing directly
acting antiviral (DAA) regimens in chronic kidney disease (CKD) patients. Recently generic …

Background There is paucity of data using direct anti-viral agents (DAA) in patients on
maintenance hemodialysis (MHD) infected with HCV-genotype 1 & 3. Aim of the study was …

To the Editor, The registration of sofosbuvir-containing regimens has changed the treatment
of hepatitis C virus (HCV) infection dramatically by achieving high sustained virological …

Results Ninety-eight patients with CKD (42% stage 1 or 2 CKD and 58% stage 3 CKD) were
included. Mean age was 62 years old, 78% were men, and 65% were white. Additionally …

Chronic hepatitis C virus infection (HCV) has a negative impact on the long-term survival of
recipients of kidney transplants. HCV should be treated in hemodialyzed patients before …

Rapid progression of chronic kidney disease (CKD) is seen in patients with hepatitis C virus
(HCV) infection compared with uninfected patients. Despite the high efficacy of direct-acting …